The Latest Cardiac and Vascular News
SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “LifeTech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its…
SHENZHEN, China, April 2, 2024 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “Lifetech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its…
SHENZHEN, China, Sept. 5, 2022 /PRNewswire/ — LifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance […]
Revenue increased by 20.4%, net profit attributable to owners of the Company increased by 34.4% after excluding certain non-recurring items SHENZHEN, China, Aug. 30, 2022 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “Lifetech”), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular […]
Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by 76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ — LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today […]
NEWS PROVIDED BY LifeTech Scientific Corporation 03 Jul, 2017, 11:56 BST FRANKFURT, Germany, July 3, 2017 /PRNewswire/ — On June 30, at the Congenital and Structural Intervention Congress (CSI) 2017 in Frankfurt, LifeTech Scientific Corporation (Stock Code: 1302.HK) announced the launch of a 3-year global post-market […]
